Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 3
1954 2
1955 3
1956 5
1957 8
1958 7
1959 2
1962 1
1964 2
1965 6
1966 8
1967 12
1968 12
1969 14
1970 12
1971 14
1972 20
1973 22
1974 20
1975 28
1976 31
1977 32
1978 32
1979 29
1980 37
1981 33
1982 33
1983 32
1984 60
1985 43
1986 43
1987 51
1988 64
1989 53
1990 59
1991 62
1992 59
1993 55
1994 45
1995 68
1996 53
1997 60
1998 61
1999 70
2000 104
2001 89
2002 93
2003 80
2004 83
2005 92
2006 84
2007 65
2008 75
2009 63
2010 59
2011 57
2012 70
2013 66
2014 70
2015 70
2016 67
2017 68
2018 64
2019 57
2020 49
2021 38
2022 38
2023 42
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

2,887 results

Results by year

Filters applied: . Clear all
Page 1
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P, Sathananthan K, Fortescue R. Poole P, et al. Cochrane Database Syst Rev. 2019 May 20;5(5):CD001287. doi: 10.1002/14651858.CD001287.pub6. Cochrane Database Syst Rev. 2019. PMID: 31107966 Free PMC article.
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume or purulence of sputum, or both. ...SELECTION CRITERIA: We included randomised studies that compared …
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbat …
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
[No authors listed] [No authors listed] Lancet. 1981 Mar 28;1(8222):681-6. Lancet. 1981. PMID: 6110912 Clinical Trial.
A controlled trial of long term domiciliary oxygen therapy has been carried out in three centres in the U.K. The 87 patients, all under 70 years of age, who took part had chronic bronchitis or emphysema with irreversible airways obstruction, severe arterial h …
A controlled trial of long term domiciliary oxygen therapy has been carried out in three centres in the U.K. The 87 patients, all und …
Erdosteine.
Dechant KL, Noble S. Dechant KL, et al. Drugs. 1996 Dec;52(6):875-81; discussion 882. doi: 10.2165/00003495-199652060-00009. Drugs. 1996. PMID: 8957158 Review.
Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains 2 blocked sulfhydryl groups which are released following first-pass metabolism. ...Co-ad …
Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of …
Cannabinoids: Medical implications.
Schrot RJ, Hubbard JR. Schrot RJ, et al. Ann Med. 2016;48(3):128-41. doi: 10.3109/07853890.2016.1145794. Epub 2016 Feb 25. Ann Med. 2016. PMID: 26912385 Review.
With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. While more randomized clinical trials a …
With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabin …
Roflumilast for COPD.
Izquierdo JL, Aparicio J. Izquierdo JL, et al. Drugs Today (Barc). 2010 Nov;46(11):823-31. doi: 10.1358/dot.2010.46.11.1521831. Drugs Today (Barc). 2010. PMID: 21225021 Review.
COPD is currently considered an inflammatory disease involving airways and lung parenchyma. The symptoms that are typical of chronic bronchitis (chronic cough and sputum production) are markers of underlying inflammation, characteristic of COPD. Roflumilast, an anti …
COPD is currently considered an inflammatory disease involving airways and lung parenchyma. The symptoms that are typical of chronic …
Faropenem medoxomil.
Gettig JP, Crank CW, Philbrick AH. Gettig JP, et al. Ann Pharmacother. 2008 Jan;42(1):80-90. doi: 10.1345/aph.1G232. Epub 2007 Dec 19. Ann Pharmacother. 2008. PMID: 18094341 Review.
DATA SYNTHESIS: The in vitro activity of faropenem has been evaluated extensively against respiratory pathogens and less extensively against aerobic gram-positive, gram-negative, and anaerobic organisms. Prospective, randomized, multicenter clinical trials have demo …
DATA SYNTHESIS: The in vitro activity of faropenem has been evaluated extensively against respiratory pathogens and less extensively against …
The history of COPD.
Petty TL. Petty TL. Int J Chron Obstruct Pulmon Dis. 2006;1(1):3-14. doi: 10.2147/copd.2006.1.1.3. Int J Chron Obstruct Pulmon Dis. 2006. PMID: 18046898 Free PMC article. Review.
The evolution of knowledge concerning COPD and its components--emphysema, chronic bronchitis, and asthmatic bronchitis--covers 200 years. The stethoscope and spirometer became important early tools in diagnosis and assessment. ...Knowledge of the pathogenesis, cours …
The evolution of knowledge concerning COPD and its components--emphysema, chronic bronchitis, and asthmatic bronchitis--covers …
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Cazzola M, et al. Pulm Pharmacol Ther. 2018 Feb;48:185-194. doi: 10.1016/j.pupt.2017.11.009. Epub 2017 Dec 9. Pulm Pharmacol Ther. 2018. PMID: 29233650 Review.
Our findings included data from ten studies involving 1278 patients and show that erdosteine is able to improve the clinical score of patients with chronic bronchitis and COPD, and also reduces the overall risk of chronic bronchitis/COPD exacerb …
Our findings included data from ten studies involving 1278 patients and show that erdosteine is able to improve the clinical score of …
Cefditoren pivoxil.
Darkes MJ, Plosker GL. Darkes MJ, et al. Drugs. 2002;62(2):319-36; discussion 337-8. doi: 10.2165/00003495-200262020-00006. Drugs. 2002. PMID: 11817976 Review.
Cefditoren penetrates rapidly into bronchopulmonary and tonsillar tissue as well as inflammatory and noninflammatory blister fluid. In two, randomised, double-blind trials involving patients with acute exacerbations of chronic bronchitis (AECB), cefditoren 20 …
Cefditoren penetrates rapidly into bronchopulmonary and tonsillar tissue as well as inflammatory and noninflammatory blister fluid. In two, …
An overview of glycopyrrolate/eFlow® CS in COPD.
Kerwin E, Ferguson GT. Kerwin E, et al. Expert Rev Respir Med. 2018 Jun;12(6):447-459. doi: 10.1080/17476348.2018.1476853. Epub 2018 May 28. Expert Rev Respir Med. 2018. PMID: 29774778 Review.
Here, we profile the newly FDA-approved LONHALA MAGNAIR (glycopyrrolate [GLY]/eFlow Closed System [CS]; 25 mcg twice daily), a nebulized long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of COPD, including chronic bronchitis and/or emp …
Here, we profile the newly FDA-approved LONHALA MAGNAIR (glycopyrrolate [GLY]/eFlow Closed System [CS]; 25 mcg twice daily), a nebulized lon …
2,887 results